WEBULL
News
OCS
21.68
+10.05%
1.98
Oculis Holding AG (OCS) Upgraded to Buy: Here's What You Should Know
NASDAQ · 4d ago
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Barchart · 4d ago
Oculis Holding Initiated at Outperform by LifeSci Capital
Dow Jones · 4d ago
Oculis Holding Price Target Announced at $55.00/Share by LifeSci Capital
Dow Jones · 4d ago
This Linde Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Benzinga · 4d ago
LifeSci Capital Initiates Coverage On Oculis Holding with Outperform Rating, Announces Price Target of $55
Benzinga · 4d ago
Oculis initiated with an Outperform at LifeSci Capital
TipRanks · 4d ago
Weekly Report: what happened at OCS last week (1124-1128)?
Weekly Report · 6d ago
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Barchart · 11/28 15:05
Weekly Report: what happened at OCS last week (1117-1121)?
Weekly Report · 11/24 10:26
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Barchart · 11/18 15:05
Pre-Market Earnings Report for November 18, 2025 : HD, PDD, MDT, BIDU, ESLT, AS, BZ, JHX, BRBR, ENR, WB, OCSL
NASDAQ · 11/17 21:00
Weekly Report: what happened at OCS last week (1110-1114)?
Weekly Report · 11/17 10:26
Oculis Holding Is Maintained at Buy by B of A Securities
Dow Jones · 11/13 17:54
Oculis Holding Price Target Cut to $29.00/Share From $30.00 by B of A Securities
Dow Jones · 11/13 17:54
B of A Securities Maintains Buy on Oculis Holding, Lowers Price Target to $29
Benzinga · 11/13 17:43
Oculis price target lowered to $29 from $30 at BofA
TipRanks · 11/13 14:55
Bank of America Securities Reaffirms Their Buy Rating on Oculis Holding (OCS)
TipRanks · 11/13 09:58
Zoom To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Tuesday
Benzinga · 11/11 13:27
Oculis Holding Is Maintained at Buy by Chardan Capital
Dow Jones · 11/11 13:19
More
Webull provides a variety of real-time OCS stock news. You can receive the latest news about Oculis Holding through multiple platforms. This information may help you make smarter investment decisions.
About OCS
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.